Schrödinger enters multi-million-dollar research collaboration with Japanese drug major

Schrödinger, a privately-held US healthcare IT company, has entered into a multi-target research collaboration directed to diseases that align with Japan’s largest drugmaker Takeda Pharmaceutical’s (TYO: 4520) core therapeutic areas of interest.

The unique collaboration will combine Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. With a focus on simplicity, speed and agility, Schrödinger will lead the multi-target discovery effort with Takeda providing protein crystal structures to aid Schrödinger in using its computational platform to guide the design of new chemical entities. Schrödinger will be responsible for its discovery costs.

Deal worth up to $170 million per program